New 'Smart Bomb' drug targets Hard-to-Treat cancers in first human trial
NCT ID NCT07085091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells that have a protein called EGFR on their surface. The trial will first find a safe dose and then check for signs that the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALX2004 (an antibody-drug conjugate that targets EGFR on cancer cells)
- What this could lead to
- If this works, it could point toward a new treatment option for people with advanced lung, head and neck, esophageal, or colorectal cancers that have stopped responding to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors, and side effects could be significant. Only a small number of people will receive the potentially effective dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
ALX Center 1
RECRUITINGSpokane, Washington, 99208, United States
-
ALX Center 2
RECRUITINGFairfax, Virginia, 22031, United States
-
ALX Center 3
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
ALX Center 4
RECRUITINGWest Valley City, Utah, 84119, United States
-
ALX Center 5
RECRUITINGHouston, Texas, 77030, United States
-
ALX Center 6
RECRUITINGPortland, Oregon, 97213, United States
-
ALX Center 7
RECRUITINGTampa, Florida, 33612, United States
-
ALX Center 8
RECRUITINGFarmington Hills, Michigan, 48334, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a registry make endoscopic procedures safer and more effective?